Neonatal fecal abundance of *Bifidobacterium longum* subspecies *infantis*

is not associated with anthropometric outcomes up to 6 months of age in

Bangladeshi infants

Cole K. Heasley[1], Veselina Stefanova[1], Celine Funk[1], Aline C. Freitas[1], Grace Li[1], Lisa G. Pell[1],

Diego G. Bassani[1,2,3,4], Karen M. O'Callaghan[5], Prakesh S. Shah[2,6], Jakaria Shawon[7], S.M.

Abdul Gaffar[7], Rashidul Haque[7], Shafiqul Alam Sarker[6], Daniel E. Roth[1,2,3,4*]

[1] Centre for Global Child Health, The Hospital for Sick Children, Toronto, Canada

[2] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[3] Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, Canada

[4] Department of Paediatrics, Hospital for Sick Children, Toronto, Canada

[5] Department of Nutritional Sciences, King's College London, London, United Kingdom

[6] Department of Pediatrics, Mount Sinai Hospital, Toronto, Canada

[7] Nutrition Research Division, International Centre for Diarrhoeal Disease Research, Bangladesh,

Dhaka, Bangladesh.

*Correspondence: Daniel Roth, daniel.roth@sickkids.ca, The Hospital for Sick Children, 555

University Ave, Toronto, Ontario, M5G 1X8, Canada.

Abstract

Background: *Bifidobacterium longum* subspecies *infantis* (*B. infantis*) abundance in the infant gut may be associated with growth and health outcomes. However, these relationships have not been widely studied in settings where *B. infantis* is a dominant early-life intestinal commensal bacteria and linear growth faltering is prevalent.

Objective: To estimate associations between neonatal fecal *B. infantis* abundance and infant anthropometric outcomes up to 6 months of age. Diarrhea and hospitalizations were examined as secondary morbidity outcomes.

Methods: We conducted a secondary analysis of data from an observational cohort of generally healthy infants in Dhaka, Bangladesh. *B. infantis* absolute abundance in stool was quantified by qPCR; for each infant (n=964), the mean abundance from 0 to 28 days of age was used as the primary exposure variable. Length-for-age, weight-for-age, and weight-for-length z-scores were derived at birth, 2, 3, and 6 months of age. Infant diarrheal and hospitalization outcomes were assessed from the end of 1 month to 2 and 6 months of age. Associations of mean *B. infantis* absolute abundance with infant outcomes were estimated using linear and modified Poisson regression, adjusted for selected sociodemographic and clinical characteristics.

Results: Mean neonatal fecal *B. infantis* abundance had a bimodal distribution, with most infants (63%) having detectable *B. infantis* by 28 days of age. Anthropometric z-score distributions were shifted down, with means below zero at all ages. Neonatal *B. infantis* absolute abundance was not associated with any anthropometric outcome at 2, 3, or 6 months of age (p>0.05 for all, n of

Heasley et al.
B. infantis abundance and infant growth

525-677), or with the risks of diarrheal events or hospitalizations (p>0.05 for both, n of 938 and

935, respectively).

Conclusions: The lack of association of neonatal *B. infantis* abundance with growth outcomes

suggests that promotion of early *B. infantis* colonization would be unlikely to improve infant

growth in populations with postnatal faltering.

Keywords: *Bifidobacterium longum* subspecies *infantis*, Anthropometry, Growth,

Gastrointestinal microbiome, Microbiota, Infant health

Introduction

Bifidobacterium longum ssp. *infantis* (*B. infantis*) is an early-life colonizer of the infant gut that is well adapted to metabolize human milk oligosaccharides (HMOs), a group of complex indigestible sugars present in human milk (1, 2). HMO metabolism by *B. infantis* produces lactic and acetic acids and other short-chain fatty acids that contribute to a lower pH in the gut lumen, inhibit proliferation of potential pathogens, and may influence immunoregulation and immune development (2-6). *B. infantis* colonization is hypothesized to improve infant health including linear and ponderal growth outcomes, possibly by reducing the risk of common morbidities such as diarrheal illness, and through effects of short-chain fatty acids on host metabolism including gluconeogenesis (7).

However, there is a lack of epidemiological evidence in support of an effect of early postnatal *B. infantis* colonization on infant growth. Few studies have been conducted in low- and middle-income countries (LMICs); in one study of infants in Bangladesh, there was a positive association between *B. infantis* and infant weight-for-age z-score (WAZ) and weight-for-length z-score (WLZ) in the first year after birth (8), but in a multivariable-adjusted analysis of cohorts in Bangladesh, Tanzania, and Pakistan, there were no associations between neonatal *B. infantis* abundance and length-for-age z-score (LAZ) or WAZ at 24 months of age (9). A key consideration in the interpretation of epidemiological studies is the wide global variation in *B. infantis* abundance – in general, it is rare or even absent among infants in high-income countries but frequently detected in LMICs (10-12), settings where infant growth faltering is most common (13, 14). Therefore, while *B. infantis* abundance might be found to explain between-individual variations in linear or ponderal growth within a study population, these associations may not explain why nearly all infants in LMICs grow more slowly than expected for their chronological age based on international growth standards (15).

In a cohort of generally healthy and mostly term-born infants in Dhaka, Bangladesh, we

previously found *B. infantis* was highly abundant in stool by 2 months of age and persisted to at

least 6 months of age; however, it was generally absent in the immediate postnatal period and

there was substantial variation in abundance in the first month (neonatal period) (16). To explore

the potential role of postnatal *B. infantis* colonization in modulating growth in early infancy, we

examined the associations between *B. infantis* abundance in the neonatal period and

anthropometric outcomes up to 6 months of age in the same cohort. In further analyses, we

estimated associations of *B. infantis* with stool pH and infant morbidity (diarrhea and

hospitalizations), considering that such relationships might represent pathways by which *B.*

infantis could influence infant growth.

Methods

Study design and participants

This secondary-use study was based on data from the Synbiotics for the Early Prevention of

Severe Infections in Infants (SEPSiS) observational cohort study (ClinicalTrials.gov

ID: NCT04012190). Approval for the original data collection was provided by The Hospital for

Sick Children Research Ethics Board (REB# 1000063899) and the International Centre for

Diarrhoeal Disease Research, Bangladesh (icddr,b) Research Ethics Committee (PR-19045).

Approval for this secondary use study was obtained from The Hospital for Sick Children

(REB#1000082019). Further details on the design and implementation of the SEPSiS

observational cohort study have been described elsewhere (16, 17). Briefly, between November

2020 and February 2022, infants were enrolled at two government healthcare facilities in Dhaka,

Bangladesh: Maternal and Child Health Training Institute and the Mohammadpur Fertility

Services and Training Centre. Infants were eligible for enrolment if they were delivered at a

study hospital, age zero (day of birth) to 4 days old, orally feeding at the time of screening, and

their caregivers were planning to maintain residence in the study catchment area until the infant

reached at least 60 days of age. Infants were ineligible for enrolment if they weighed <1500 g at

birth, had a major congenital anomaly of the gastrointestinal tract, death or major surgery were

likely within the first week after birth, were on mechanical ventilation or cardiac support, were

receiving or prescribed parenteral antibiotics, were enrolled in an ongoing clinical trial involving

the administration of probiotics and/or prebiotics, resided in the same household as another

infant under 60 days of age (excluding twins), prenatal or postpartum/postnatal non-dietary

probiotic supplements were used by the infant's mother or provided directly to the infant,

multiple gestation of the mother exceeded two, or the mother was diagnosed with HIV infection

and/or history of receiving anti-retroviral drug(s) for a presumed HIV infection. For each model

assessed, this study included all SEPSiS observational cohort participants who had relevant data.

Stool sample collection

Study personnel collected infant stool samples using standardized procedures according to one of

three schedules (A, B, or C). Infants in schedules A and B had up to 11 routine stool samples

collected (days 0 or 1, 3 or 4, 6 or 7, 10, 14, 21, 28, 35, 60, 90, and 180), whereas infants in

schedule C only had up to 3 routine stool samples collected (on the day of enrollment and twice

more on randomly assigned visits up to day 60). Because schedules A and B used the same

sample collection schedules, and had similar numbers of samples per infant, and no other

differences in the protocol that would influence the current analysis, the groups were combined

for all analyses in this study. In hospital or the infant's home, stool samples were collected using

a wrapped plastic sheet or plastic wrap-lined diaper, then manually homogenized and aliquoted

into appropriate vials. For samples collected by study workers (all schedule A/B samples, 46% of

schedule C samples), aliquots intended for qPCR were placed in the vapour phase of liquid

nitrogen within 20 minutes of defecation, and aliquots for stool pH measurements were stored in

a cold box at 2-8ºC (never frozen). For schedule C samples that could not be collected directly

by study workers (54% of samples), the infant's caregiver was instructed to place the stool

sample in a cold box (maintained at 2-8ºC) within 20 minutes of defecation until it was

transported to the field office by study staff. All stool aliquots were placed into the vapour phase

of liquid nitrogen within 6 hours of defecation, before transport to icddr,b for storage at ≤-70ºC

until analysis.

Sample processing and laboratory analyses

Stool sample selection and quantification of *B. infantis* absolute abundance have been described

in detail elsewhere (16). Briefly, total DNA was extracted from 100-150 mg of stool using

QIAamp Fast DNA Stool Mini Kit (QIAGEN, Germany). Total DNA mass was quantified using

a Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). *B. infantis* was quantified using

qPCR with primer-probes specific to *B. infantis* (18). Cell counts were based on standard curves

generated using pure cultures of *B. infantis* ATCC 15697, and absolute abundance was

normalized to total DNA mass and expressed as log *B. infantis* cells per µg total DNA. For

samples with undetectable *B. infantis* (*i.e.*, did not amplify or had cell counts below the limit of

detection of the qPCR assay), a value of 2.5 log cells/µg DNA was imputed for the absolute

Heasley et al.
B. infantis abundance and infant growth

abundance. This value corresponds to the median of half the limit of detection normalized to

each undetected sample DNA mass.

Aliquots for measuring stool pH were brought to room temperature before mixing 1 g of stool

with deionized water to achieve a total sample volume of 10 mL. Stool pH was measured twice

per sample using portable pH testers (Hanna, USA). If the difference between the two pH

measurements was greater than 0.5 pH units, a third measurement was taken, and the mean of the

two closest pH values was used in analyses.

Clinical and anthropometric data collection

Routine study visits were conducted five times at the infant's home or via phone call up to and

including 14 days of age, then weekly until 60 days, then at 3 and 6 months. Study staff collected

information about feeding practices (7-day recall), infant receipt of antibiotics (since last study

visit), diarrheal episodes, and hospital admissions (17). Diarrheal episodes were based on a

caregiver response of 'yes' when asked if the infant had diarrhea described as the "frequency of

stool is too often, the quantity of stool is too much, and/or the consistency is too loose compared

to the usual," since the prior study visit or in the preceding 7 days, including the day of the

encounter. Hospitalizations were verified and recorded by Study Medical Officers and were

defined on the basis of admission to hospital for any reason other than injury or elective surgery.

Anthropometric measurement methods were adapted from standardized procedures from the

INTERGROWTH-21st study (19). Trained study staff measured infant length and weight on the

day of enrolment and during scheduled home visits at 2, 3, and 6 months postnatal age. Length

was measured using a wooden length board to the nearest 1 mm (Shorr board, Weight and

Measure LLC, USA) and weight was measured with a Seca 334 or 354 digital scale to the

nearest 1 g (Seca, USA). Each measurement was obtained twice and averaged; if the difference

between two measurements was greater than 7 mm or 50 g for length and weight, respectively, a

third measurement was taken. If a third measurement was taken, the two closest measurements

were used to calculate the average.

For measurements on days 0-2 of age, baseline LAZ and WAZ were derived using

INTERGROWTH-21st Newborn Size growth curves (20). Beyond 2 days of age, including visits

at 2, 3, and 6 months postnatal age, the WHO Child Growth Standards were used to derive LAZ

and WAZ for term infants (gestational age ≥260 days) (21), whereas for preterm infants

(gestational age <260 days) older than 2 days postnatal age, LAZ and WAZ were generated

using the INTERGROWTH-21st Postnatal Growth for Preterm Infants growth curves (22). All

WLZs were derived from WHO Child Growth Standards as the index is independent of age. In

instances of implausible values (infant length or weight decreasing over time or LAZ/WAZ ≥±6

or WLZ ≥±5), values and trajectories were examined independently by two reviewers to

determine if any measurements should be removed. In total, individual growth trajectories for 92

(4.8%) infants were flagged for investigation and 58 (0.86%) discrete length or weight

measurements were removed from 56 infant trajectories (resulting in the exclusion of one full

infant trajectory). For each infant, anthropometric measurements were grouped according to the

following age intervals: baseline (days 0-4), 2 months (days 59-75), 3 months (days 76-110), and

6 months (days 160-200).

Statistical analysis

Baseline characteristics were described using medians (with 25th and 75th centiles) for continuous

data and counts (proportions) for categorical data. Scatterplots with LOESS curves were

generated for all *B. infantis*-anthropometric associations investigated to visualize trends in

bivariate relationships.

B. infantis absolute abundance in the first 28 days after birth was summarized at the infant level

using the mean of each infant's analyzed samples from 0-28 days (neonatal period). Mean

neonatal *B. infantis* absolute abundance refers to the measure of each infant's abundance level

averaged across all the infant's stool samples with qPCR abundance data from days 0-28.

Several summary measures of neonatal *B. infantis* absolute abundance were tested and the mean

was selected for primary analyses (see Supplementary Methods, **Table S1 and Figures S1-3**).

Associations between mean *B. infantis* absolute abundance and anthropometric indices at

specified time points were estimated using linear regression models. All models with

anthropometric outcomes included adjustment for the same anthropometric index measured at

baseline. Sample sizes for the otherwise unadjusted models included only those infants with

complete covariate data and who were included in the corresponding multivariable-adjusted

analysis. Additional covariates in the adjusted regression models included: breastfeeding status

assessed at or closest to age 28 days, infant sex, hospital enrolment site, mode of delivery,

gestational age at birth, neonatal infant systemic antibiotics (ever/never), maternal BMI at

enrolment, maternal education, maternal age, the number of infants within the household under 5

years of age, and household asset index quintile. Asset index was calculated for all infants

enrolled in the SEPSiS observational cohort and a related clinical trial (23) using principal

component analysis of a checklist of household assets and scored based on the first principal

component, which was then converted to quintiles. The primary outcome was LAZ and the

secondary outcomes were WAZ and WLZ.

In sensitivity analyses, we used the following alternative approaches to define neonatal *B.*

infantis abundance: 1) area under the curve (of absolute abundance by age, as a continuous

variable); 2) *B. infantis* absolute abundance expressed as a categorical dichotomous variable

defined as undetectable (all stool samples within the first 28 days of age with undetectable *B.*

infantis) or detectable (at least one stool sample with detectable *B. infantis* within the first 28

days of age). We also conducted analyses in which we altered the period during which *B. infantis*

mean abundance was summarized (0-14 or 0-60 days of age). We also conducted a cross-

sectional analysis using the single absolute abundance measurement that was closest in time to

the 2-month anthropometric measurement (and collected within the interval of 59-75 days). We

repeated the primary analysis in a subset of the cohort restricted to infants assigned to specimen

collection schedules A/B. Lastly, we estimated the association between baseline anthropometric

indices and neonatal *B. infantis* abundance as the outcome, and we performed the primary

analyses without adjustment for the baseline measures.

Associations between median neonatal stool pH and LAZ, WAZ, and WLZ at 2, 3, and 6 months

were assessed using linear regression models with the same covariates as described above. In a

sensitivity analysis, we conducted a cross-sectional analysis by using the pH measurement

closest in time to each anthropometric measurement (and within the same age interval used for

the corresponding anthropometric value). We used linear mixed effects regression models to

estimate the association between *B. infantis* absolute abundance and stool pH (corresponding

values generated for the same stool sample), using all samples collected in the neonatal period.

The mean stool pH of samples with detectable versus undetectable *B. infantis* was compared

using the Kruskal-Wallis test.

To estimate associations of mean neonatal *B. infantis* abundance with diarrheal events from 29 to

60 days (2 months) of age and hospitalizations (excluding trauma/injury or elective surgeries)

from 29 to 180 days (6 months) of age, infants were categorized as never/ever having had a

diarrheal event or hospitalization during the defined period. Modified Poisson regression models

(with robust standard errors) were used to estimate relative risks of diarrhea and hospitalization

by mean neonatal *B. infantis* abundance. In adjusted models, covariates included breastfeeding

status assessed on or closest to 28 days of age, mode of delivery, gestational age, neonatal

antibiotic exposure, maternal education, and household asset index quintile.

We considered the use of path analysis to examine if any associations between *B. infantis*

abundance and anthropometric indices could be explained by mediating roles of stool pH or

clinical events, but these analyses were not pursued due to null associations of *B. infantis*

abundance with anthropometric indices.

The Holm method was used to account for multiple comparisons and maintain an overall α of

0.05 for each set of analyses (one set refers to all analyses presented within each table). All

analyses were conducted using R statistical software (Version 4.4.1) (24). All statistical code

used in analyses for this study was independently reviewed by a second data analyst.

Results

Of 1939 infants enrolled in the SEPSiS observational cohort, 964 infants (50%) had at least one neonatal *B. infantis* absolute abundance measurement and at least one eligible anthropometric measure (**Figure 1**). Infants were predominantly born full-term (92%), via c-section (52%), and 68% were exclusively breastfed up to 28 days of age (**Table 1, Table S2** stratified by infant sex). Of the 3903 stool samples collected in the neonatal period, 2982 (76%) underwent qPCR testing. From 0-28 days of age, infants assigned to schedules A/B and C contributed a median (25th, 75th centiles) of 6.0 (2.0, 7.0) and 1.0 (1.0, 3.0) stool samples for qPCR analysis, respectively. There were 1164 infants (60%) with at least one neonatal stool pH measurement and at least one anthropometric measurement in one of the age intervals assessed. There were 935 infants (48%) with a neonatal *B. infantis* abundance measurement who also had available morbidity-related data up to 6 months of age.

The distribution of mean neonatal *B. infantis* absolute abundances was bimodal, with a median (25th,75th percentiles) of 3.7 log cells/μg DNA (2.5, 7.6) (**Figure 2**). When the age range was reduced to 0-14 days, the median reduced to 2.9 (2.5, 6.9) log cells/μg DNA and when expanded to 0-60 days, the median abundance increased to 5.0 (2.5, 7.7) log cells/μg DNA. Among the 966 infants with at least one neonatal qPCR measurement from 0-28 days of age, 608 had *B. infantis* detected in at least one stool sample (63%) and had a median (25th, 75th) of their mean neonatal abundance values of 6.6 log cells/μg DNA (2.6, 8.9); among infants with undetectable *B. infantis* in all stool samples from 0-28 days of age (37%), the mean neonatal abundance values were all uniformly 2.5 log cells/μg DNA (corresponding to the imputed lower limit of quantification). The mean (SD) value of infant-level median stool pH values was 5.7 (0.6).

277   Anthropometric z-scores were approximately normally distributed but shifted downwards such

278   that all means were below zero at all timepoints (**Figure 2** and **Table S3**). Infants included in this

279   sub-study were generally representative of the overall SEPSiS observational cohort with respect

280   to growth patterns (**Table S3**).

Heasley et al.
B. infantis abundance and infant growth

Figure 1. Study flow diagram showing the number of infants from the SEPSiS observational study cohort who contributed to the primary and secondary analyses in this study. Bold lines indicated pathway to primary analysis sample (shown in dashed lines).

[a] Complete covariates include: enrolment site, infant sex, breastfeeding status at 28 days of age (if available) or at age most proximal to 28 days, mode of delivery, gestational age at birth, infant antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of infants within the household under 5 years of age, and household asset index quintile.

Table 1. Baseline characteristics of infants with a mean *B. infantis* abundance value and at least one anthropometric measure.

Characteristic	Median (25th, 75th centiles) or count (%) (n=964)
Enrolment site	
Mohammadpur Fertility Services and Training Centre	574 (60)
Maternal and Child Health Training Institute	390 (40)
Sex	
Male	467 (48)
Female	497 (52)
Baseline LAZ [a, b]	-0.84 (-1.5, -0.17)
Baseline WAZ [a, b]	-0.88 (-1.6, -0.21)
Baseline WLZ [a, b]	-0.61 (-1.4, 0.17)
Mode of delivery	
Vaginal	463 (48)
C-section	501 (52)
Stool collection schedule [c]	
A/B	360 (37)
C	604 (63)
Breastfeeding status by 28 days of age	
Exclusively breastfed	660 (68)
Predominantly breastfed	174 (18)
Partially breastfed or not breastfed	130 (13)
Gestational age at birth [a]	
Term ($\geq$ 260 days)	884 (92)
Preterm (<260 days)	76 (7.9)
Antibiotic use by 28 days of age	
Yes	104 (11)
No	860 (89)
Maternal BMI (kg/m^2) [a]	26 (23, 29)
Maternal education	
Little to no schooling [d]	272 (28)
Secondary incomplete	335 (35)
Secondary complete or higher	357 (37)
Maternal age (years)	24 (20, 28)
Infants within the household under 5 years of age [a]	0 (0, 1)
Household asset index quintile [a, e]	
1 (lowest wealth)	176 (18)
2	195 (20)
3	198 (21)
4	199 (21)
5 (highest wealth)	185 (19)
Stool *B. infantis* absolute abundance measurements per infant, 0-28 days of age	
Infants with 1 sample	420 (44)

Infants with 2-4 samples	221 (23)
Infants with 5-7 samples	323 (34)

Abbreviations: BMI, body mass index; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score; qPCR, quantitative polymerase chain reaction.

[a] n < 964: baseline LAZ, n=930; baseline WAZ, n=924; baseline WLZ, n=880; gestational age at birth, n=960; maternal BMI, n=925; number of infants within household under 5 years of age, n=948; asset index, n=953.

[b] Mean and SD of anthropometric z-score distributions are shown in Table S3.

[c] Infants in schedule A/B had up to 7 routine stool samples collected in the first month of age (days 0 or 1, 3 or 4, 6 or 7, 10, 14, 21, and 28). Infants in schedule C had up to 3 routine stool samples collected (day of enrolment and twice more on randomly assigned visits up to 60 days of age).

[d] Little to no schooling was defined as: no schooling at all; having completed *qawmi madrasa* but no other schooling; or, up to 5 years of schooling or *alia madrasa*.

[e] Quintiles of a score derived by first component of principal component analysis from a checklist of household assets from all SEPSiS infants (observational cohort and associated trial). Higher quintile relates to ownership of more assets.

Heasley et al.
B. infantis abundance and infant growth

Figure 2. Distributions of anthropometric indices, mean *B. infantis* abundance, and median stool pH. Kernel density plots for infants with at least one *B. infantis* qPCR measurement and complete covariates of A) LAZ (Baseline, n=894; 2 months, n=652; 3 months, n=677; 6 months, n=560), B) WAZ (Baseline, n=888; 2 months, n=649; 3 months, n=677; 6 months, n=562), and C) WLZ (Baseline, n=838; 2 months, n=609; 3 months, n=634; 6 months, n=525). Standard normal distributions (mean=0, SD=1) are shown as solid black lines in each panel. Histograms of D) mean neonatal *B. infantis* absolute abundance (n=964) and E) median neonatal stool pH (n=1238). Abbreviations: LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.

There were no associations between mean neonatal *B. infantis* absolute abundance and LAZ,

WAZ, or WLZ, at 2, 3, or 6 months of age, in unadjusted or adjusted models (**Table 2**; **Figure**

S4). Neonatal *B. infantis* absolute abundance was not associated with baseline LAZ, WAZ, or

WLZ (**Table S4**). Inferences remained unchanged when participants were stratified by sex

(**Table S5)**, and in sensitivity analyses (**Tables S6-11**) with these exceptions: in the analysis

restricted to infants enrolled in schedules A/B, there was a significant positive association of

mean neonatal *B. infantis* with LAZ at 3 months of age and a significant negative association of

B. infantis with WLZ at 2 months of age, but both associations were attenuated to the null and no

longer significant at 6 months of age (**Table S12**). To investigate if the higher number of

samples in schedule A/B may have influenced the associations, the analysis was rerun using two

random samples per infant to resemble total sample numbers in schedule C, with selection

simulated 1000 times. Based on this further analysis, we did not find evidence that the greater

number of stool samples per infant in schedules A/B during the 0-28 day period explained the

discrepancy in findings between the sub-analysis of schedule A/B and the primary analysis

(**Table S13**).

Table 2. Associations of mean *B. infantis* absolute abundance (0-28 days of age) and infant anthropometric indices at 2, 3, and 6 months of age.

Outcome, Infant age	Unadjusted model[a]			Adjusted model[b]		
	n	Difference in anthropometric z-score (95% CI) for each 1 log cell/µg DNA increase in mean *B. infantis* absolute abundance	p-value	n	Difference in anthropometric z-score (95% CI) for each 1 log cell/µg DNA increase in mean *B. infantis* absolute abundance	p-value
LAZ						
2 months	652	-0.014 (-0.041, 0.014)	0.3	652	-0.0013 (-0.027, 0.025)	>0.9
3 months	677	0.011 (-0.016, 0.038)	0.4	677	0.022 (-0.0043, 0.049)	0.1
6 months	560	-0.011 (-0.041, 0.018)	0.5	560	0.0080 (-0.022, 0.038)	0.6
WAZ						
2 months	649	-0.012 (-0.038, 0.014)	0.4	649	-0.0032 (-0.029, 0.023)	0.8
3 months	677	0.0035 (-0.023, 0.030)	0.8	677	0.012 (-0.015, 0.040)	0.4
6 months	562	0.0023 (-0.030, 0.034)	0.9	562	0.0093 (-0.024, 0.043)	0.6
WLZ						
2 months	609	0.0065 (-0.030, 0.043)	0.7	609	-0.0096 (-0.048, 0.029)	0.6
3 months	634	-0.0097 (-0.042, 0.023)	0.6	634	-0.020 (-0.055, 0.015)	0.3
6 months	525	0.0024 (-0.036, 0.041)	>0.9	525	-0.016 (-0.056, 0.025)	0.4

Abbreviations: CI, confidence interval; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.

[a] Baseline measurement (on day of enrolment) of the same parameter as the outcome was included as a covariate in all linear regression models.

[b] Additional covariates in adjusted models: enrolment site, infant sex, breastfeeding status at 28 days of age (if available) or at age most proximal to 28 days, mode of delivery, gestational age at birth, infant antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of infants within the household under 5 years of age, and household asset index quintile.

In all individual neonatal stool samples (n=2118 samples), there was a 0.093 (95% CI: 0.084, 0.10; p <0.001) decrease in stool pH per one unit increase in log *B. infantis* cells/μg of DNA. There was evidence that the relationship between *B. infantis* absolute abundance with stool pH may be non-linear (**Figure S5**). When *B. infantis* abundance was dichotomized, the mean pH of stool samples (SD) with detectable and undetectable *B. infantis* was 5.5 (0.68) and 6.0 (0.54), respectively (p <0.001). Median stool pH up to 28 days after birth was significantly associated with WAZ at 2 months and WLZ at 2 and 3 months of age in unadjusted models (**Table 3** and **Figure S6**), but only the association with WAZ at 3 months remained statistically significant after covariate adjustment (Table 3). There was no association between stool pH and LAZ at any timepoint (**Table 3**). Stool pH was not associated with any anthropometric indices in cross-sectional analyses, which used the stool pH value for the sample collected closest in time to the anthropometric measurement (**Table S14**).

Of the infants who had available *B. infantis* absolute abundance data and had not exited the study by the end of 2 or 6 months, 36 (3.8%) infants had at least one diarrheal event between 29 and 60 days of age (n=938), and 78 (8.3%) had at least one hospitalization event between 29 and 180 days of age (n=935). Mean *B. infantis* absolute abundance was not associated with the risk of an infant experiencing a diarrheal event (RR = 0.96 (95%CI: 0.82, 1.1) per 1 log *B. infantis* cells/μg of DNA increase; p = 0.5) or hospitalization (RR = 1.0 (95%CI: 0.90, 1.1) per 1 log *B. infantis* cells/μg of DNA increase; p>0.9).

Table 3. Associations of median neonatal stool pH (0-28 days of age) and infant anthropometric indices at 2, 3, and 6 months of age.

Outcome, Infant age	Unadjusted model [a]			Adjusted model [b]		
	n	Difference in growth outcome per 1 unit decrease in pH (95% CI)	p-value	n	Difference in growth outcome per 1 unit decrease in pH (95% CI)	p-value
LAZ						
2 months	854	-0.017 (-0.11, 0.078)	0.7	854	0.014 (-0.079, 0.11)	0.8
3 months	843	0.024 (-0.073, 0.12)	0.6	843	0.060 (-0.039, 0.16)	0.2
6 months	695	-0.062 (-0.18, 0.053)	0.3	695	-0.0039 (-0.13, 0.12)	>0.9
WAZ						
2 months	853	0.12 (0.028, 0.21)	0.01[c]	853	0.088 (-0.0062, 0.18)	0.07
3 months	842	0.17 (0.073, 0.26)	<0.001[d]	842	0.15 (0.049, 0.25)	0.004[d]
6 months	698	0.11 (-0.016, 0.23)	0.09	698	0.090 (-0.041, 0.22)	0.2
WLZ						
2 months	812	0.19 (0.067, 0.31)	0.002[d]	812	0.094 (-0.040, 0.23)	0.2
3 months	796	0.18 (0.070, 0.30)	0.002[d]	796	0.11 (-0.010, 0.24)	0.07
6 months	659	0.17 (0.030, 0.31)	0.02[c]	659	0.092 (-0.060, 0.24)	0.2

Abbreviations: CI, confidence interval; LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.

[a] Baseline measurement (on day of enrolment) of the same parameter as the outcome was included as a covariate in all linear regression models.

[b] Additional covariates in adjusted models: enrolment site, infant sex, breastfeeding status at 28 days of age (if available) or at age most proximal to 28 days of age, mode of delivery, gestational age at birth, infant antibiotic exposure by 28 days of age, maternal BMI, maternal education, maternal age, number of infants within the household under 5 years of age, and household asset index quintile.

[c] No longer statistically significant after Holm's adjustment.

[d] Remained statistically significant after Holm's adjustment.

Heasley et al.
B. infantis abundance and infant growth

Discussion

In a cohort of generally healthy infants in Dhaka, Bangladesh, *B. infantis* stool absolute abundance in the neonatal period was not associated with anthropometric indices up to 6 months of age. As expected, stool pH was inversely associated with stool *B. infantis* abundance (2) but we did not corroborate prior findings of an inverse association between stool pH and LAZ (25). Although there was an inverse association of stool pH with infant WAZ in early infancy, the magnitude of the association was small (~0.1 SD per 1 unit change in stool pH), especially given the narrow range of observed pH values. Additionally, this relationship could not be explained by the pH-lowering effect of *B. infantis*; therefore, if the relationship between stool pH and weight represents a causal pathway, it may be attributable to other components of the microbiome, or it may be confounded by unmeasured aspects of the diet or medications that influence both stool pH and weight gain (26).

The null associations between *B. infantis* abundance and anthropometric indices in the first 6 months postnatal age were broadly consistent with a prior study that did not find relationships between neonatal *B. infantis* abundance and LAZ (n=292) or WAZ (n=472) at 24 months of age in Bangladesh, Pakistan, and Tanzania (9). In the Bangladeshi and Tanzanian cohorts, there was a positive association of enrolment (*i.e.*, birth) LAZ with *B. infantis* abundance (9), which raises the possibility of reverse causality. However, we did not observe a similar association in the SEPSiS observational cohort, and our inferences were the same in models with and without adjustment for baseline LAZ.

Recent systematic reviews of the effects of probiotics in infants have included few studies of *B. infantis*, or when included, were generally administered in combination with other probiotic species (27-29), or have focused on *B. infantis* but did not address growth outcomes (30). Two

trials of the *B. infantis* probiotic EVC001 conducted in the United States did not find effects on

achieved weight/weight gain or length among term exclusively breastfed infants (31) or preterm

infants (32). Similarly, two trials in Spain showed no effects of *B. infantis* probiotics on infant

weight or length (33, 34). However, in a single-blind randomized controlled trial involving 2- to

6-month old infants with severe acute malnutrition in Dhaka, Bangladesh (n= 67), infants treated

with *B. infantis* EVC001 daily for 28 days had a significantly higher WAZ and mid-upper arm

circumference compared to the placebo group at 28 days post-intervention, despite no effect on

LAZ (35, 36). Some studies of probiotics with multiple species including *B. infantis* reported

positive effects on weight gain in very preterm infants in Australia and New Zealand (37) or very

low birth weight infants in the United States (38) and Germany (39), but it is uncertain whether

the effects were specifically attributable to *B. infantis*. In a sensitivity analysis in the present

study, which was restricted to a subset of infants who had stool sampled more frequently

(schedule A/B; 40-42% of infants in primary analyses), *B. infantis* was positively associated with

LAZ and negatively associated with WLZ at 3 months of age but these associations were

substantially attenuated by 6 months of age and were not explained by a greater precision of *B.*

infantis abundance measurement due to higher sample numbers. Therefore, we did not consider

these findings to have altered the overall conclusion that neonatal *B. infantis* abundance is

unrelated to growth in the first 6 months postnatal age.

A meta-analysis of trials investigating the effect of probiotics containing *B. infantis* on preterm

and/or very low birth weight infants found that administering probiotics reduced all-cause

mortality (14 trials with 4292 infants), necrotizing enterocolitis (15 trials with 3626 infants), and

late onset sepsis (13 trials with 4123 infants) (30). However, only 5 of the 16 studies included

100 or more infants in each trial arm and all studies used a combination of probiotics that

included *B. infantis*, rather than *B. infantis* alone. In the present study, we did not find

associations between *B. infantis* neonatal abundance and either diarrheal events or

hospitalizations; however, we acknowledge that these analyses may have been underpowered

due to a low number of events. We did not assess associations with cause-specific

hospitalizations due to the low number of events related to discrete causes. However, we

acknowledge that the use of all-cause hospitalization as the outcome measure may have biased

the association towards the null if there were only certain morbidities for which there were true

associations with *B. infantis* abundance.

Examining individual-level risk factors, such as *B. infantis* abundance, may identify sources of

inter-individual variations in growth within a population; however, inter-individual variations

may not provide insights into a population-level phenomenon (15, 40). Growth faltering in

LMICs is not restricted to a subset of infants with stunting within a population, but rather the

whole population distributions of anthropometric indices are shifted downwards (14, 15). Given

the high prevalence of *B. infantis* colonization in populations with endemic postnatal growth

faltering (10-12), and the absence of associations of *B. infantis* with growth at the infant level as

observed here, there is unlikely to be an important role for early postnatal *B. infantis* colonization

in mitigating growth-faltering in such settings.

Several limitations of the present study should be considered. Stool *B. infantis* abundance was

used as a proxy of intestinal *B. infantis* abundance but may not reflect variability in abundance

within the intestine (41); however, methods for obtaining luminal samples from infants'

intestinal tracts rely on procedures that would be invasive, infeasible and unethical in a large

cohort study in this age group. We focused our analysis on *B. infantis* colonization in the

neonatal period because most infants were eventually colonized with *B. infantis* by 1-2 months

of age (16); therefore, we were unable to examine the effects of longer-term colonization.

Additionally, we only explored the associations between infant growth and the abundance of

naturally occurring *B. infantis* without consideration of strain-level distinctions. Beneficial

effects from commensals or probiotics may be strain-specific; for example, HMO gene clusters

are highly conserved across *B. infantis* strains, but the presence of specific genes within clusters

differ among *B. infantis* strains (12, 42, 43). The study population had a high C-section rate,

which influences early gut microbial succession patterns (16); however, this rate of C-section is

comparable to other studies in this setting (35, 44).

Conclusion

Stool absolute abundance of *B. infantis* in the first month after birth was not associated with

linear or ponderal growth up to 6 months of age in generally healthy infants in Dhaka,

Bangladesh. Based on these findings, promotion of early *B. infantis* colonization through

interventions such as *B. infantis* probiotic administration in the neonatal period may not be

expected to improve growth outcomes in generally healthy infants born in settings with high

prevalence of natural *B. infantis* colonization and where postnatal faltering is widespread.

Author contributions

Conceptualization or design of the work (CKH, DER, KMOC, LGP, DGB, PS, SS, VS); Data generation/ collection (ACF, AG, GL, JS, RH, SS); Supervision of field or lab activities (AG, RH, SS); Analysis of data (CKH, CF); Supervision of data analysis (DER); Writing manuscript (CKH, VS); Revising manuscript critically (ACF, AG, CF, DER, GL, JS, KMOC, LGP, DGB, PS, SS, VS).

Acknowledgements

We would like to thank the families who participated in the SEPSiS cohort study, as well as the other SEPSiS project co-investigators and study personnel who were involved in data collection and laboratory analysis.

Funding

This research was funded by The Bill and Melinda Gates Foundation, grant number INV-007389 to The Hospital for Sick Children and grant GR-02268 to the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). The funders had no role in the study design, data collection, statistical analysis, preparation of the manuscript, or the decision to submit the manuscript for publication.

Data availability

All data and code used for the analyses are available on Borealis:

https://doi.org/10.5683/SP3/PWPMGK

Conflict of interest

The authors report no conflict of interest.

References

1.	Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res. 2015;77(1-2):229-35, doi:10.1038/pr.2014.156.

2.	Frese SA, Hutton AA, Contreras LN, Shaw CA, Palumbo MC, Casaburi G, et al. Persistence of Supplemented Bifidobacterium longum subsp. infantis EVC001 in Breastfed Infants. mSphere. 2017;2(6), doi:10.1128/msphere.00501-17.

3.	Henrick BM, Rodriguez L, Lakshmikanth T, Pou C, Henckel E, Arzoomand A, et al. Bifidobacteria-mediated immune system imprinting early in life. Cell. 2021;184(15):3884-98.e11, doi:10.1016/j.cell.2021.05.030.

4.	Huda MN, Ahmad SM, Alam MJ, Khanam A, Kalanetra KM, Taft DH, et al. Bifidobacterium Abundance in Early Infancy and Vaccine Response at 2 Years of Age. Pediatrics. 2019;143(2), doi:10.1542/peds.2018-1489.

5.	Laursen MF, Sakanaka M, Von Burg N, Mörbe U, Andersen D, Moll JM, et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. Nature Microbiology. 2021;6(11):1367-82, doi:10.1038/s41564-021-00970-4.

6.	Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469(7331):543-7, doi:10.1038/nature09646.

7.	Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, De Preter V, et al. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. The Journal of Physiology. 2017;595(2):541-55, doi:10.1113/jp272613.

8.	Vatanen T, Ang QY, Siegwald L, Sarker SA, Le Roy CI, Duboux S, et al. A distinct clade of Bifidobacterium longum in the gut of Bangladeshi children thrives during weaning. Cell. 2022;185(23):4280-97 e12, doi:10.1016/j.cell.2022.10.011.

9.	Colston JM, Taniuchi M, Ahmed T, Ferdousi T, Kabir F, Mduma E, et al. Intestinal Colonization With Bifidobacterium longum Subspecies Is Associated With Length at Birth, Exclusive Breastfeeding, and Decreased Risk of Enteric Virus Infections, but Not With Histo-Blood Group Antigens, Oral Vaccine Response or Later Growth in T. Frontiers in Pediatrics. 2022;10, doi:10.3389/fped.2022.804798.

10.	Taft DH, Lewis ZT, Nguyen N, Ho S, Masarweh C, Dunne-Castagna V, et al. Bifidobacterium Species Colonization in Infancy: A Global Cross-Sectional Comparison by Population History of Breastfeeding. Nutrients. 2022;14(7):1423, doi:10.3390/nu14071423.

11.	Lawley B, Otal A, Moloney-Geany K, Diana A, Houghton L, Heath A-LM, et al. Fecal Microbiotas of Indonesian and New Zealand Children Differ in Complexity and Bifidobacterial Taxa during the First Year of Life. Applied and Environmental Microbiology. 2019;85(19), doi:10.1128/aem.01105-19.

12.	Shao Y, Wang S, Gichuki BM, Stares MD, Rozday T, Kumar N, et al. Genomic Atlas of Early Life Bifidobacteria for Rational Development of Next-Generation Probiotics for Infant Health. Sneak Peak2025.

13.	UNICEF, WHO, The World Bank. Levels and trends in child malnutrition: UNICEF / WHO / World Bank Group Joint Child Malnutrition Estimates: Key findings of the 2023 edition. New York: UNICEF and WHO; 2023.

14.	Victora CG, Christian P, Vidaletti LP, Gatica-Domínguez G, Menon P, Black RE. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. The Lancet. 2021;397(10282), doi:10.1016/S0140-6736(21)00394-9.

15.	Roth DE, Krishna A, Leung M, Shi J, Bassani DG, Barros AJD. Early childhood linear growth faltering in low-income and middle-income countries as a whole-population condition:

analysis of 179 Demographic and Health Surveys from 64 countries (1993-2015). Lancet Glob
Health. 2017;5(12):e1249-e57, doi:10.1016/S2214-109X(17)30418-7.
16. Freitas AC, Li G, Shawon J, Qamar H, Pell LG, Kabir M, et al. Abundance of
Bifidobacterium species in the infant gut microbiota and associations with maternal-infant
characteristics in Dhaka, Bangladesh. 2025.
17. Fung A, Heasley C, Pell LG, Bassani DG, Shah PS, Morris SK, et al. Severe infection
among young infants in Dhaka, Bangladesh: effect of case definition on incidence estimates.
2024.
18. Lawley B, Munro K, Hughes A, Hodgkinson AJ, Prosser CG, Lowry D, et al.
Differentiation of *Bifidobacterium longum* subspecies *longum* and *infantis* by quantitative PCR
using functional gene targets. PeerJ. 2017;5:e3375, doi:10.7717/peerj.3375.
19. Cheikh Ismail L, Knight H, Bhutta Z, Chumlea W. Anthropometric protocols for the
construction of new international fetal and newborn growth standards: the INTERGROWTH-21st
Project. BJOG: An International Journal of Obstetrics & Gynaecology. 2013;120(s2):42-7,
doi:10.1111/1471-0528.12125.
20. The International Fetal and Newborn Growth Consortium for the 21st Century.
INTERGROWTH-21st Newborn Size 2024 [Available from: https://intergrowth21.com/tools-
resources/newborn-size.
21. WHO. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-
length, weight-for-height and body mass index-for-age: methods and development. Geneva:
WHO; 2006.
22. The International Fetal and Newborn Growth Consortium for the 21st Century.
INTERGROWTH-21st Postnatal Growth of Preterm Infants 2024 [Available from:
https://intergrowth21.com/tools-resources/postnatal-growth-preterm-infants.
23. Pell LG, Qamar H, Bassani DG, Heasley C, Funk C, Chen CY, et al. Neonatal
administration of Lactiplantibacillus plantarum ATCC 202195 with or without
fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial. mSphere.
2025;10(3):e0103224, doi:10.1128/msphere.01032-24.
24. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation
for Statistical Computing, Vienna, Austria; 2024.
25. Hossain MS, Das S, Gazi MA, Alam MA, Haque NMS, Mahfuz M, et al. Association of
faecal pH with childhood stunting: Results from a cross-sectional study. BMJ Paediatrics Open.
2019;3(1):e000549, doi:10.1136/bmjpo-2019-000549.
26. Yamamura R, Inoue KY, Nishino K, Yamasaki S. Intestinal and fecal pH in human health.
Frontiers in Microbiomes. 2023;2, doi:10.3389/frmbi.2023.1192316.
27. Panchal H, Athalye-Jape G, Rao S, Patole S. Growth and neuro-developmental
outcomes of probiotic supplemented preterm infants-a systematic review and meta-analysis.
Eur J Clin Nutr. 2023;77(9):855-71, doi:10.1038/s41430-023-01270-2.
28. Catania J, Pandit NG, Ehrlich JM, Zaman M, Stone E, Franceschi C, et al. Probiotic
Supplementation for Promotion of Growth in Children: A Systematic Review and Meta-Analysis.
Nutrients. 2021;14(1), doi:10.3390/nu14010083.
29. Guo H, Fan M, Hou T, Li Y, Wang S, Wang X, et al. Efficacy and Safety of
Bifidobacterium longum Supplementation in Infants: A Meta-Analysis of Randomized Controlled
Trials. Foods 2023, Vol 12, Page 4451. 2023-12-12;12(24), doi:10.3390/foods12244451.
30. Batta VK, Rao SC, Patole SK, Batta VK, Rao SC, Patole SK. Bifidobacterium infantis as
a probiotic in preterm infants: a systematic review and meta-analysis. Pediatric Research 2023
94:6. 2023;94(6), doi:10.1038/s41390-023-02716-w.
31. Smilowitz JT, Moya J, Breck MA, Cook C, Fineberg A, Angkustsiri K, et al. Safety and
tolerability of Bifidobacterium longum subspecies infantis EVC001 supplementation in healthy
term breastfed infants: a phase I clinical trial. BMC Pediatrics. 2017;17(1), doi:10.1186/s12887-
017-0886-9.

Heasley et al.
B. infantis abundance and infant growth

32.   Bajorek S, Duar RM, Corrigan M, Matrone C, Winn KA, Norman S, et al. B. infantis
EVC001 Is Well-Tolerated and Improves Human Milk Oligosaccharide Utilization in Preterm
Infants in the Neonatal Intensive Care Unit. Frontiers in Pediatrics. 2022;9,
doi:10.3389/fped.2021.795970.
33.   Manzano S, De Andrés J, Castro I, Rodríguez JM, Jiménez E, Espinosa-Martos I. Safety
and tolerance of three probiotic strains in healthy infants: a multi-centre randomized, double-
blind, placebo-controlled trial. Beneficial Microbes. 2017;8(4):569-78,
doi:10.3920/bm2017.0009.
34.   Escribano J, Ferré N, Gispert-Llaurado M, Luque V, Rubio-Torrents C, Zaragoza-
Jordana M, et al. Bifidobacterium longum subsp infantis CECT7210-supplemented formula
reduces diarrhea in healthy infants: a randomized controlled trial. Pediatric Research.
2018;83(6):1120-8, doi:10.1038/pr.2018.34.
35.   Nuzhat S, Hasan SMT, Palit P, Islam MR, Mahfuz M, Islam MM, et al. Effects of probiotic
and synbiotic supplementation on ponderal and linear growth in severely malnourished young
infants in a randomized clinical trial. Scientific Reports. 2023;13(1), doi:10.1038/s41598-023-
29095-w.
36.   Barratt MJ, Nuzhat S, Ahsan K, Frese SA, Arzamasov AA, Sarker SA, et al.
Bifidobacterium infantis treatment promotes weight gain in Bangladeshi infants with severe
acute malnutrition. Science Translational Medicine. 2022-04-13;14(640),
doi:10.1126/scitranslmed.abk1107.
37.   Jacobs SE, Group ftPS, Tobin JM, Group ftPS, Opie GF, Group ftPS, et al. Probiotic
Effects on Late-onset Sepsis in Very Preterm Infants: A Randomized Controlled Trial. Pediatrics.
2013/12/01;132(6), doi:10.1542/peds.2013-1339.
38.   Al-Hosni M, Duenas M, Hawk M, Stewart LA, Borghese RA, Cahoon M, et al. Probiotics-
supplemented feeding in extremely low-birth-weight infants. J Perinatol. 2012;32(4):253-9,
doi:10.1038/jp.2011.51.
39.   Härtel C, Pagel J, Spiegler J, Buma J, Henneke P, Zemlin M, et al. Lactobacillus
acidophilus/Bifidobacterium infantis probiotics are associated with increased growth of VLBWI
among those exposed to antibiotics. Scientific Reports. 2017;7(1), doi:10.1038/s41598-017-
06161-8.
40.   Rose G. Sick individuals and sick populations. International Journal of Epidemiology.
1985;14:32-8, doi:10.1093/ije/30.3.427.
41.   Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S, et al.
Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with
Unique Host and Microbiome Features. Cell. 2018/09/06;174(6), doi:10.1016/j.cell.2018.08.041.
42.   Locascio RG, Desai P, Sela DA, Weimer B, Mills DA. Broad Conservation of Milk
Utilization Genes in *Bifidobacterium longum* subsp. *infantis* as Revealed by Comparative
Genomic Hybridization. Applied and Environmental Microbiology. 2010;76(22):7373-81,
doi:10.1128/aem.00675-10.
43.   Duar RM, Casaburi G, Mitchell RD, Scofield LNC, Ortega Ramirez CA, Barile D, et al.
Comparative Genome Analysis of Bifidobacterium longum subsp. infantis Strains Reveals
Variation in Human Milk Oligosaccharide Utilization Genes among Commercial Probiotics.
Nutrients. 2020;12(11):3247, doi:10.3390/nu12113247.
44.   National Institute of Population Research and Training (NIPORT) and ICF. Bangladesh
Demographic and Health Survey: Final Report. Dhaka, Bangladesh, and Rockville, Maryland,
USA; 2022.

Heasley et al.
B. infantis abundance and infant growth